Nighttime problems constitute a significant burden on the quality of life of patients with seasonal allergic rhinitis (SAR). The aim of this study was to evaluate the effectiveness of montelukast on nighttime AR symptoms.
Methods
In seven multicenter, double-blind, parallel-group trials, nighttime problems were assessed as the nighttime symptoms score (NSS), an average of three individual symptom scores: difficulty going to sleep, nighttime awakening, and nasal congestion on awakening (each rated 0 = none to 3 = severe). Patients (aged 15–82 years) were randomized to receive montelukast, 10 mg (n = 1751), placebo (n = 1557), or the positive control loratadine, 10 mg (n = 1616).
Results
In a combined analysis, changes from baseline (mean ± SE) in NSS were -0.28 ± 0.01, -0.16 ± 0.01, and —0.24 ± 0.01 for the montelukast, placebo, and loratadine groups, respectively. Difference versus placebo in least-squares mean change from baseline were —0.11 (95% confidence interval, -0.14, -0.08; p ≤ 0.001) for montelukast and -0.09 (-0.12, -0.06; p ≤ 0.001) for loratadine. Strong baseline correlations (R > 0.70; p < 0.001) of NSS and two of its individual symptoms with the sleep domain of the validated Rhinoconjunctivitis Quality of Life Questionnaire support the validity and importance of measuring nighttime morbidity in SAR. Furthermore, a clinically important benefit of montelukast on the nighttime impact of SAR was shown using an analysis anchored on the Patient's Global Evaluation.
Conclusion
These data underscore the importance of nighttime problems in patients with SAR and the need to treat nighttime symptoms. In these studies, montelukast significantly improved the NSS, a clinically relevant and valid measure in patients with SAR.
Get full access to this article
View all access options for this article.
References
1.
NathanR.A., MeltzerE.O., SelnerJ.C.Prevalence of allergic rhinitis in the United States.J Allergy Clin Immunol99: S808–S814, 1997.
LundbackB.Epidemiology of rhinitis and asthma.Clin Exp Allergy28(suppl. 2): 3–10, 1998.
4.
HowarthP.H.Leukotrienes in rhinitis.Am J Respir Crit Care Med161: S133–S136, 2000.
5.
SanderC., and RajakulasingamK.Leukotriene receptor antagonists for the treatment of allergic rhinitis.Clin Exp Allergy32: 4–7, 2002.
6.
VolovitzB., OsurS.L., BernsteinJ.M.Leukotriene C4 release in upper respiratory mucosa during natural exposure to ragweed in ragweed-sensitive children.J Allergy Clin Immunol82: 414–418, 1988.
7.
SkonerD.P., LeeL., DoyleW.J.Nasal physiology and inflammatory mediators during natural pollen exposure.Ann Allergy65: 206–210, 1990.
8.
LindenM., SvenssonC., AnderssonM.Circulating eosinophil/basophil progenitors and nasal mucosal cytokines in seasonal allergic rhinitis.Allergy54: 212–219, 1999.
9.
GeorgitisJ.W., StoneB.D., and GottschlichG.Nasal inflammatory mediator release in ragweed allergic rhinitis: Correlation with cellular influx into nasal secretions.Int Arch Allergy Appl Immunol96: 231–237, 1991.
10.
WangD., ClementP., SmitzJ.Correlations between complaints, inflammatory cells and mediator concentrations in nasal secretions after nasal allergen challenge and during natural allergen exposure.Int Arch Allergy Immunol106: 278–285, 1995.
11.
MiadonnaA., MilazzoN., GibelliS.Nasal response to a single antigen challenge in patients with allergic rhinitis—Inflammatory cell recruitment persists up to 48 hours.Clin Exp Allergy29: 941–949, 1999.
12.
MiadonnaA., TedeschiA., LeggieriE.Behavior and clinical relevance of histamine and leukotrienes C4 and B4 in grass pollen-induced rhinitis.Am Rev Respir Dis136: 357–362, 1987.
13.
OkudaM., WataseT., MezawaA.The role of leukotriene D4 in allergic rhinitis.Ann Allergy60: 537–540, 1988.
14.
NumataT., KonnoA., YamakoshiT.Comparative role of peptide leukotrienes and histamine in the development of nasal mucosal swelling in nasal allergy.Ann Otol Rhinol Laryngol108: 467–473, 1999.
15.
LipworthB.J.Emerging role of antileukotriene therapy in allergic rhinitis.Clin Exp Allergy31: 1813–1821, 2001.
16.
ReissT.F., KnorrB., MalmstromK.Clinical efficacy of montelukast in adults and children.Clin Exp Allergy Rev1: 264–273, 2001.
17.
MeltzerE.O., MalmstromK., LuS.Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial.J Allergy Clin Immunol105: 917–922, 2000.
18.
MicheleT.M., LuS., MaliceM.P.Combination of montelukast and loratadine in seasonal allergic rhinitis: A analysis of three spring studies.J Allergy Clin Immunol105(suppl. 1): S387, 2000.
19.
NayakA., PhilipG., LuS.Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled trial performed in the fall.Ann Allergy Asthma Immunol88: 592–600, 2002.
20.
PhilipG., MalmstromK., HampelF.C.Jr.Montelukast for treating seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled trial performed in the spring.Clin Exp Allergy32: 1020–1028, 2002.
21.
ChervinskyP., PhilipG., MaliceM.P.Montelukast for treating fall allergic rhinitis: Effect of pollen exposure in 3 studies.Ann Allergy Asthma Immunol92: 367–373, 2004.
22.
van AdelsbergJ., LaForceC.F., WeinsteinS.F.Randomized controlled trial evaluating clinical benefit of montelukast for treating spring seasonal allergic rhinitis.Ann Allergy Asthma Immunol.90: 214–222, 2003.
23.
van AdelsbergJ., PhilipG., PedinoffA.J.Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period.Allergy58: 1268–1276, 2003.
24.
JuniperE.F.Impact of upper respiratory allergic diseases on quality of life.J Allergy Clin Immunol101: S386–S391, 1998.
25.
LavieP., GertnerR., ZomerJ.Breathing disorders in sleep associated with “microarousals” in patients with allergic rhinitis.Acta Otolaryngol92: 529–533, 1981.
26.
McNicholasW.T., TarloS., ColeP.Obstructive apneas during sleep in patients with seasonal allergic rhinitis.Am Rev Respir Dis126: 625–628, 1982.
27.
YoungT., FinnL., and KimH.Nasal obstruction as a risk factor for sleep-disordered breathing.J Allergy Clin Immunol99: S757–S762, 1997.
28.
MeltzerE.O.Quality of life in adults and children with allergic rhinitis.J Allergy Clin Immunol108: S45–S53, 2001.
29.
JaeschkeR., SingerJ., and GuyattG.H.Measurement of health status. Ascertaining the minimal clinically important difference.Control Clin Trials10: 407–415, 1989.
30.
JuniperE.F., and GuyattG.H.Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis.Clin Exp Allergy21: 77–83, 1991.
31.
BousquetJ., Van CauwenbergeP., KhaltaevN. and ARIA Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma.J Allergy Clin Immunol108: S147–S334, 2001.
32.
ThompsonA.K., JuniperE., and MeltzerE.O.Quality of life in patients with allergic rhinitis.Ann Allergy Asthma Immunol85: 338–348, 2000.
33.
EllisA.K., DayJ.H., and LundieM.J.Impact on quality of life during an allergen challenge research trial.Ann Allergy Asthma Immunol83: 33–39, 1999.
34.
MeltzerE.O., CasaleT.B., NathanR.A.Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis.Ann Allergy Asthma Immunol83: 311–317, 1999.
35.
JenA., BaroodyF., de TineoM.As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis.J Allergy Clin Immunol105: 732–738, 2000.
36.
JuniperE.F., RohrbaughT., and MeltzerE.O.A questionnaire to measure quality of life in adults with nocturnal allergic rhinoconjunctivitis.J Allergy Clin Immunol111: 484–490, 2003.
37.
HouserS.M., MamikogluB., AquinoB.F.Acoustic rhinometry findings in patients with mild sleep apnea.Otolaryngol Head Neck Surg126: 475–480, 2002.
KremerB., Den HartogH.M., and JollesJ.Relationship between allergic rhinitis, disturbed cognitive functions, and psychological well-being.Clin Exp Allergy32: 1310–1315, 2002.
40.
SimonsF.E.R.Learning impairment and allergic rhinitis.Allergy Asthma Proc17: 185–189, 1996.
41.
JuniperE.F.Quality of life questionnaires: Does statistically significant = clinically important?J Allergy Clin Immunol102: 16–17, 1998 (Editorial).
42.
JuniperE.F., GuyattG.H., GriffithL.E.Interpretation of rhinoconjunctivitis quality of life questionnaire data.J Allergy Clin Immunol98: 843–845, 1996.
43.
JuniperE.F., GuyattG.H., WillanA.Determining a minimal important change in a disease-specific Quality of Life Questionnaire.J Clin Epidemiol47: 81–87, 1994.
44.
SantanelloN.C., ZhangJ., SeidenbergB.What are minimal important changes for asthma measures in a clinical trial?Eur Respir J14: 23–27, 1999.
